The latest financial statement is for the year ending 2025-12-31.
| Cash Flow | 2025-12-31 |
|---|---|
| Net loss | -10,206,517 |
| Forgiveness of unrelated vendor payables | 2,142,297 |
| Forgiveness of related party receivables | 126,275 |
| Depreciation | 1,828 |
| Change in fair value of deferred underwriting fee - paid in common stock | -196,000 |
| Change in the fair value of warrant liability | -54,312 |
| Loss on issuance of common stock in connection with the surrendar of warrants | -1,740,000 |
| Fair value of common stock to be issued for contingent liability | 7,360,000 |
| Due from related party, current | 3,427,000 |
| Prepaid and other current assets | -324,609 |
| Accounts payable and accrued expenses | -4,035,340 |
| Accrued interest, related parties | -215,903 |
| Due to related party | -62,467 |
| Net cash used in operating activities | -9,963,318 |
| Loans to iris acquisition corp | 775,000 |
| Purchases of property and equipment | 13,108 |
| Net cash used in investing activities | -788,108 |
| Gross proceeds from issuance of common stock for pipe investment | 10,556,500 |
| Payment of transaction costs | 2,563,738 |
| Proceeds from issuance of short-term debt, related party | 4,340,000 |
| Repayment of short-term debt, related party | 1,300,000 |
| Net cash provided by financing activities | 11,032,762 |
| Net change in cash | 281,336 |
| Cash, beginning of the period | 56,319 |
| Cash, end of the period | 337,655 |
Liminatus Pharma, Inc. (LIMNW)
Liminatus Pharma, Inc. (LIMNW)